Raphael P Viscidi
Overview
Explore the profile of Raphael P Viscidi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
2432
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bordi L, DAuria A, Frasca F, Mazzotta V, Mazzetti P, Fracella M, et al.
Med Microbiol Immunol
. 2024 Nov;
213(1):25.
PMID: 39527317
The recent outbreak of monkeypox virus (MPXV) has caused global concern. How the virus evades the interferon (IFN) response is still poorly understood. We analyzed type I/II IFN (IFN-I/II) expression...
2.
Fracella M, Mancino E, Nenna R, Virgillito C, Frasca F, DAuria A, et al.
Eur J Immunol
. 2024 Mar;
54(5):e2350682.
PMID: 38522030
SARS-CoV-2 typically causes mild symptoms in children, but evidence suggests that persistent immunopathological changes may lead to long COVID (LC). To explore the interplay between LC and innate immunity, we...
3.
Viscidi R, Rowley T, Bossis I
Int J Mol Sci
. 2023 Jun;
24(12).
PMID: 37372999
Safe and effective T cell vaccines are needed for the treatment or prevention of cancers as well as infectious agents where vaccines for neutralizing antibodies have performed poorly. Recent research...
4.
Xiao J, Li Y, Rowley T, Huang J, Yolken R, Viscidi R
Sci Rep
. 2023 Jan;
13(1):1288.
PMID: 36690687
Toxoplasma gondii can infect the host brain and trigger neuroinflammation. Such neuroinflammation might persist for years if the infection is not resolved, resulting in harmful outcomes for the brain. We...
5.
Scordio M, Frasca F, Santinelli L, Sorrentino L, Pierangeli A, Turriziani O, et al.
Clin Immunol
. 2022 Jun;
241:109068.
PMID: 35764258
The presence of anti-IFN neutralizing antibodies (NAB) has been reported in critically ill COVID-19 patients. We found that 87.5% (7/8) of HIV-1 patients co-infected with SARS-CoV-2 had serum anti-IFN-I NAB...
6.
Frasca F, Scordio M, Santinelli L, Gabriele L, Gandini O, Criniti A, et al.
Eur J Immunol
. 2022 Apr;
52(7):1120-1128.
PMID: 35419822
A significant number of COVID-19 patients were shown to have neutralizing antibodies (NAB) against IFN; however, NAB specificity, fluctuation over time, associations with biochemical and hematological parameters, and IFN gene...
7.
Xiao J, Bhondoekhan F, Seaberg E, Yang O, Stosor V, Margolick J, et al.
Clin Infect Dis
. 2021 Jan;
73(7):e2270-e2277.
PMID: 33388768
Background: Clinically useful predictors for fatal toxoplasmosis are lacking. We investigated the value of serological assays for antibodies to whole Toxoplasma antigens and to peptide antigens of the Toxoplasma cyst...
8.
Paul P, Hammer A, Rositch A, Burke A, Viscidi R, Silver M, et al.
J Infect Dis
. 2020 Sep;
223(8):1423-1432.
PMID: 32870982
Background: Understanding the source of newly detected human papillomavirus (HPV) in middle-aged women is important to inform preventive strategies, such as screening and HPV vaccination. Methods: We conducted a prospective...
9.
Simons B, Cannella F, Rowley D, Viscidi R
Cancer Immunol Immunother
. 2020 Feb;
69(4):641-651.
PMID: 32016503
Prostate cancer is a candidate for immunotherapy because cancer cells express tissue-specific proteins that can be therapeutic targets. However, immune checkpoint inhibitors and active immunization have performed poorly in clinical...
10.
Li Y, Severance E, Viscidi R, Yolken R, Xiao J
Infect Immun
. 2019 Jun;
87(8).
PMID: 31182619
, a common neurotropic parasite, is increasingly being linked to neuropsychiatric disorders, including schizophrenia, Alzheimer's disease, and Parkinson's disease. However, the pathogenic mechanisms underlying these associations are not clear. can...